Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 8.25 HKD 4.56% Market Closed
Market Cap: 20.5B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Simcere Pharmaceutical Group Ltd stock under the Base Case scenario is 12.42 HKD. Compared to the current market price of 8.25 HKD, Simcere Pharmaceutical Group Ltd is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
12.42 HKD
Undervaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3
P/S
P/S
Price to Sales
3
vs History
56
vs Industry
40
Median 3Y
2.7
Median 5Y
3
Industry
2.4
Forward
2.5
More Details
26.7
P/E
P/E
Price to Earnings
26.7
vs History
18
vs Industry
25
Median 3Y
18
Median 5Y
18.2
Industry
20.8
Forward
15.4
More Details
17.9
P/OCF
P/OCF
Price to OCF
17.9
vs History
49
vs Industry
27
Median 3Y
17.4
Median 5Y
17.2
Industry
15.4
More Details
78
P/FCFE
P/FCFE
Price to FCFE
78
vs History
5
vs Industry
8
Median 3Y
49.7
Median 5Y
-10.8
Industry
22.8
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
54
vs Industry
29
Median 3Y
2.4
Median 5Y
2.7
Industry
2
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
45
vs Industry
43
Median 3Y
2.5
Median 5Y
2.8
Industry
2.5
Forward
2.4
More Details
3.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.5
vs History
49
vs Industry
57
Median 3Y
3.3
Median 5Y
3.4
Industry
4.9
More Details
16.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.8
vs History
61
vs Industry
22
Median 3Y
18.3
Median 5Y
21.4
Industry
12.7
Forward
11.1
More Details
16.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.8
vs History
72
vs Industry
25
Median 3Y
20.8
Median 5Y
24.7
Industry
15.8
Forward
13.7
More Details
17.1
EV/OCF
EV/OCF
Enterprise Value to OCF
17.1
vs History
45
vs Industry
29
Median 3Y
16.7
Median 5Y
16.5
Industry
14
More Details
78.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
78.3
vs History
0
vs Industry
7
Median 3Y
17.9
Median 5Y
-18.2
Industry
18.3
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
50
vs Industry
36
Median 3Y
1.8
Median 5Y
2.1
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
Simcere Pharmaceutical Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
21B HKD 3 26.7 16.8 16.8
US
Eli Lilly and Co
NYSE:LLY
757B USD 17 72.3 42.2 46.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.9B USD 4.2 26.6 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.3 21.1 13.9 15.8
CH
Roche Holding AG
SIX:ROG
233.1B CHF 4 20.2 11.3 13.4
UK
AstraZeneca PLC
LSE:AZN
176.2B GBP 4.2 32.4 126.9 193.7
CH
Novartis AG
SIX:NOVN
199.3B CHF 4.4 18.9 11.4 14.6
US
Merck & Co Inc
NYSE:MRK
220.6B USD 3.4 12.9 8.7 10.3
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
139.2B USD 2.2 17.4 8.4 11.9
P/E Multiple
Earnings Growth PEG
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
Average P/E: 27.6
26.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
72.3
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.6
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
21.1
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.2
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.4
36%
0.9
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
US
Merck & Co Inc
NYSE:MRK
12.9
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
Average EV/EBITDA: 396.9
16.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.2
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.4
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
Average EV/EBIT: 1 701.2
16.8
28%
0.6
US
Eli Lilly and Co
NYSE:LLY
46.6
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.7
21%
9.2
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.9
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.